Four Twenty dot Net

SECUREL(R) prescription drugs best pain meds for arthritis and OxyContin(R) are registered trademarks of TheraQuest Biosciences, Inc., and Purdue Pharma LP., respectively. SECUREL(R) dosage remote consultation online pharmacies forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It has been tramadol prozac interaction developed using TheraQuest's proprietary abuse deterrent extended release drug delivery system (SECUREL(R)). /) is a private, prescription drugs development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need.

Despite their limitations, current treatments for acute online pharmacy prescription required and chronic pain yield worldwide sales in excess of $30 billion. TheraQuest is funded in part by BioAdvance, the pain management Biotechnology Greenhouse of Southeastern Pennsylvania digoxin and Ben Thayne Technology Partners of Southeastern Pennsylvania. Unfortunately, it is easy to defeat the sustained release mechanim of such dosage forms, making them subject to drug diversion and drug abuse. About TheraQuest TheraQuest Biosciences, Inc. SECUREL(R) is TheraQuest's proprietary abuse deterrent extended release technology for oral abusable drugs. Abusers to extract the active buy propecia online cheap drug from the dosage form arthritis medicine using com solvents, including alcohol.

BLUE BELL, butalbital side effects Pa., / / -- TheraQuest Biosciences, Inc. About SECUREL(R) Recent experience with extended release opioid pain relievers has shown that intentional crushing or extraction of the active ingredient from pain management the dosage form by addicts erythromycin estolate and recreational drug users can destroy the timed-release mechanism and result in a rapid surge of drug into the bloodstream. pain pills Najib Babul of TheraQuest Biosciences, Inc., 1-610-272-2071 Web Site. A development stage viagra online reviews pain management company today announced that the U.S. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. It is also exceedingly difficult for I.V. TheraQuest's strategy is to use its expertise to identify, develop pain pills and commercialize product candidates with best pain relief arthritis strong market potential that have lower development costs and reduced regulatory risk than new chemical entities.

Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended fluoxetine withdrawal release strong opioid. TheraQuest is headquartered in Blue Bell, Pennsylvania. Najib Babul, , Chief Executive Officer of TheraQuest stated, "Sustained release opioids are the standard sodium hyaluronate of care for the pain relievers management of chronic pain. It shows robust efficacy in various animal models of acute pain, inflammatory pain and neuropathic pain. Serious side-effects indinavir and death have been reported from such misuse.

TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology. TQ-1015 is significantly more potent than many current oral therapies, including morphine and oxycodone. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin(R), thereby minimizing abuse by recreational drug users and drug addicts." About TQ-1015 TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain. TQ-1015 will compete in the $8.3 billion U.S.